Uses of DPP-IV inhibitors
DC CAFC
First Claim
Patent Images
1. A method of treating type II diabetes mellitus comprising administering to a patient in need thereof a pharmaceutically effective oral amount of 1-[(4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and a pharmaceutically effective amount of metformin, which is from 300 mg to 1000 mg once or twice a day, or delayed-release metformin in a dose of 500 mg to 1000 mg once or twice a day or 500 mg to 2000 mg once a day.
0 Assignments
Litigations
1 Petition
Accused Products
Abstract
The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
304 Citations
26 Claims
- 1. A method of treating type II diabetes mellitus comprising administering to a patient in need thereof a pharmaceutically effective oral amount of 1-[(4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and a pharmaceutically effective amount of metformin, which is from 300 mg to 1000 mg once or twice a day, or delayed-release metformin in a dose of 500 mg to 1000 mg once or twice a day or 500 mg to 2000 mg once a day.
- 10. A method of treating type 2 diabetes or pre-diabetes comprising administering to a patient in need thereof a therapeutically effective oral dose of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in combination with a therapeutically effective dose of metformin, which is 500 mg, 850 mg or 1000 mg metformin as a single dose with a total daily dose of metformin of 500-2850 mg, or which is 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in delayed release form.
-
18. A method of treating type II diabetes mellitus comprising administering to a patient in need thereof a pharmaceutically effective oral amount of 1-[(4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine which is an oral daily dose of from 2.5 mg to 10 mg, and a pharmaceutically effective amount of metformin.
-
19. A method of treating type II diabetes mellitus comprising administering to a patient in need thereof a pharmaceutically effective oral amount of 1-[(4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine which is an oral daily dose of 5 mg, and a pharmaceutically effective amount of metformin.
- 20. A method of treating type 2 diabetes or pre-diabetes comprising administering to a patient in need thereof a therapeutically effective oral dose of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in combination with a therapeutically effective dose of metformin, wherein the 1-[(R4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is administered in an oral dosage of from 0.5 mg to 50 mg.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeBoehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
-
Original AssigneeBoehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
-
InventorsDugi, Klaus, Himmelsbach, Frank, Mark, Michael
-
Primary Examiner(s)Weddington, Kevin E
-
Application NumberUS12/946,193Publication NumberTime in Patent Office1,219 DaysField of Search514/263.21, 514/635, 514/866US Class Current514/263.21CPC Class CodesA61K 31/155 Amidines (), e.g. guanidine...A61K 31/197 the amino and the carboxyl ...A61K 31/4184 condensed with carbocyclic ...A61K 31/4985 Pyrazines or piperazines or...A61K 31/5025 ortho- or peri-condensed wi...A61K 31/52 Purines, e.g. adenineA61K 31/522 having oxo groups directly ...A61K 31/7048 having oxygen as a ring het...A61K 45/06 Mixtures of active ingredie...A61P 1/00 Drugs for disorders of the ...A61P 15/00 Drugs for genital or sexual...A61P 17/02 for treating wounds, ulcers...A61P 19/02 for joint disorders, e.g. a...A61P 29/00 Non-central analgesic, anti...A61P 3/00 Drugs for disorders of the ...A61P 3/04 Anorexiants; Antiobesity ag...A61P 3/06 AntihyperlipidemicsA61P 3/10 for hyperglycaemia, e.g. an...A61P 37/06 Immunosuppressants, e.g. dr...A61P 43/00 Drugs for specific purposes...View All
